Trial · NCT00525902
Adalimumab (Humira) in the Treatment of Refractory Non-infectious Uveitis
NCT00525902, Phase 2, Completed, Oregon Health and Science University; results first posted 2012-04-09
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Adalimumab (Humira) in the Treatment of Refractory Non-infectious Uveitis. Trials, record NCT00525902. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00525902
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Adalimumab (Humira) in the Treatment of Refractory Non-infectious Uveitis
- NCT number
- NCT00525902
- Status
- Completed
- Phases
- Phase 2
- Enrollment
- 31 participants, actual
- Lead sponsor
- Oregon Health and Science University
- Conditions
- Uveitis
- Interventions
- Adalimumab
- First posted
- 2007-09-06
- Last updated
- 2012-04-11
- Results first posted
- 2012-04-09
- Limitations and caveats
2 had to discontinue for methodologic reasons (pregnancy, loss to follow up wk 42), leading to their classification as failures. As a three-center study, differences between the study population are possible.
Source ClinicalTrials.gov
Registered outcomes2
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Cumulative Endpoint | 10 weeks | Improvement in at least one of these criteria without significant worsening in any of them. 1) improvement by 2 or more lines of best-corrected Snellen visual acuity in at least one eye; (2) reduction in dose of systemic corticosteroid or other immunosuppressive therapy by at least 50%; (3) two-step improvement in control of ocular inflammation; and (4) reduction of cystoid macular edema and other inflammatory signs on angiography. |
| Primary | Cumulative Endpoint | 50 Weeks | Improvement in at least one of these criteria without significant worsening in any of them. 1) improvement by 2 or more lines of best-corrected Snellen visual acuity in at least one eye; (2) reduction in dose of systemic corticosteroid or other immunosuppressive therapy by at least 50%; (3) two-step improvement in control of ocular inflammation; and (4) reduction of cystoid macular edema and other inflammatory signs on angiography. |
Source ClinicalTrials.gov
Outcomes2
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Cumulative Endpoint | 10 weeks | participants | NUMBER | |
| PRIMARY | Cumulative Endpoint | 50 Weeks | Participants characterized as clinical responders at 10 weeks were allowed to continue in the study. | participants | NUMBER |
Source ClinicalTrials.gov
Results by group2
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Cumulative Endpoint | Adalimumab | 21 | participants | ||
| Cumulative Endpoint | Adalimumab | 12 | participants |
Source ClinicalTrials.gov
Participant flow5
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Adalimumab | 31 | |
| Overall Study | 10 Weeks | Adalimumab | 30 | |
| Overall Study | 50 Weeks | Adalimumab | 12 | |
| Overall Study | COMPLETED | Adalimumab | 30 | |
| Overall Study | NOT COMPLETED | Adalimumab | 1 |
Source ClinicalTrials.gov
Adverse events4
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Headache | General disorders | Adalimumab | 3 | 31 | 3 |
| other | Joint pain | General disorders | Adalimumab | 3 | 31 | 3 |
| serious | Hypoglycemic Coma | Blood and lymphatic system disorders | Adalimumab | 1 | 31 | 1 |
| serious | Stroke | Vascular disorders | Adalimumab | 1 | 31 | 1 |
Source ClinicalTrials.gov
Adverse event totals3
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Adalimumab | ||
| Total, other adverse events | Adalimumab | 6 | 31 |
| Total, serious adverse events | Adalimumab | 1 | 31 |
Source ClinicalTrials.gov
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT00525902
GET https://conductscience.org/api/trials/v1/NCT00525902/registered